Delta-Fly Pharmaの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/03/03 | 1,246 | 1,450 | 1,218 | 1,431 | +194 | +15.7% | 2,248,100 |
2023/03/02 | 1,328 | 1,369 | 1,170 | 1,237 | -49 | -3.8% | 2,827,700 |
2023/03/01 | 1,446 | 1,510 | 1,286 | 1,286 | -179 | -12.2% | 2,657,500 |
2023/02/28 | 1,391 | 1,504 | 1,375 | 1,465 | +84 | +6.1% | 4,041,700 |
2023/02/27 | 1,200 | 1,432 | 1,184 | 1,381 | +229 | +19.9% | 5,418,300 |
2023/02/24 | 1,107 | 1,152 | 1,096 | 1,152 | +27 | +2.4% | 264,700 |
2023/02/22 | 1,152 | 1,165 | 1,114 | 1,125 | -49 | -4.2% | 530,200 |
2023/02/21 | 1,192 | 1,244 | 1,155 | 1,174 | ±0 | ±0% | 746,000 |
2023/02/20 | 1,176 | 1,240 | 1,155 | 1,174 | -29 | -2.4% | 794,800 |
2023/02/17 | 1,241 | 1,277 | 1,182 | 1,203 | -43 | -3.5% | 1,687,500 |
2023/02/16 | 1,145 | 1,324 | 1,119 | 1,246 | +107 | +9.4% | 3,098,300 |
2023/02/15 | 1,043 | 1,148 | 1,038 | 1,139 | +141 | +14.1% | 1,396,300 |
2023/02/14 | 1,047 | 1,047 | 990 | 998 | -79 | -7.3% | 657,900 |
2023/02/13 | 1,022 | 1,082 | 1,010 | 1,077 | +47 | +4.6% | 618,200 |
2023/02/10 | 1,021 | 1,040 | 1,002 | 1,030 | -4 | -0.4% | 295,500 |
2023/02/09 | 1,038 | 1,060 | 1,031 | 1,034 | -20 | -1.9% | 252,400 |
2023/02/08 | 1,063 | 1,070 | 1,042 | 1,054 | -18 | -1.7% | 248,600 |
2023/02/07 | 1,069 | 1,090 | 1,052 | 1,072 | ±0 | ±0% | 283,200 |
2023/02/06 | 1,069 | 1,102 | 1,052 | 1,072 | -7 | -0.6% | 303,800 |
2023/02/03 | 1,148 | 1,162 | 1,074 | 1,079 | -91 | -7.8% | 721,900 |
2023/02/02 | 1,142 | 1,199 | 1,134 | 1,170 | +36 | +3.2% | 355,300 |
2023/02/01 | 1,134 | 1,165 | 1,106 | 1,134 | +5 | +0.4% | 227,000 |
2023/01/31 | 1,111 | 1,135 | 1,095 | 1,129 | -3 | -0.3% | 231,600 |
2023/01/30 | 1,106 | 1,153 | 1,086 | 1,132 | +8 | +0.7% | 613,700 |
2023/01/27 | 1,180 | 1,184 | 1,120 | 1,124 | -70 | -5.9% | 556,600 |
2023/01/26 | 1,258 | 1,267 | 1,130 | 1,194 | -64 | -5.1% | 1,168,300 |
2023/01/25 | 1,214 | 1,295 | 1,208 | 1,258 | +38 | +3.1% | 968,100 |
2023/01/24 | 1,242 | 1,265 | 1,197 | 1,220 | +7 | +0.6% | 899,800 |
2023/01/23 | 1,214 | 1,233 | 1,185 | 1,213 | -1 | -0.1% | 653,700 |
2023/01/20 | 1,130 | 1,228 | 1,130 | 1,214 | +66 | +5.7% | 537,600 |
2023/01/19 | 1,106 | 1,170 | 1,091 | 1,148 | +28 | +2.5% | 358,300 |
2023/01/18 | 1,089 | 1,131 | 1,068 | 1,120 | +1 | +0.1% | 499,800 |
2023/01/17 | 1,151 | 1,167 | 1,103 | 1,119 | -53 | -4.5% | 759,900 |
2023/01/16 | 1,206 | 1,224 | 1,138 | 1,172 | -78 | -6.2% | 823,700 |
2023/01/13 | 1,234 | 1,265 | 1,201 | 1,250 | +31 | +2.5% | 485,700 |
2023/01/12 | 1,317 | 1,322 | 1,212 | 1,219 | -96 | -7.3% | 724,400 |
2023/01/11 | 1,349 | 1,379 | 1,305 | 1,315 | -34 | -2.5% | 421,500 |
2023/01/10 | 1,325 | 1,350 | 1,216 | 1,349 | -6 | -0.4% | 962,100 |
2023/01/06 | 1,221 | 1,371 | 1,213 | 1,355 | +126 | +10.3% | 861,800 |
2023/01/05 | 1,210 | 1,240 | 1,175 | 1,229 | +18 | +1.5% | 341,900 |
2023/01/04 | 1,275 | 1,299 | 1,195 | 1,211 | -61 | -4.8% | 734,800 |
2022/12/30 | 1,218 | 1,281 | 1,185 | 1,272 | +84 | +7.1% | 876,800 |
2022/12/29 | 1,185 | 1,203 | 1,142 | 1,188 | +3 | +0.3% | 335,400 |
2022/12/28 | 1,147 | 1,220 | 1,118 | 1,185 | +23 | +2% | 653,000 |
2022/12/27 | 1,049 | 1,177 | 1,042 | 1,162 | +137 | +13.4% | 528,500 |
2022/12/26 | 998 | 1,030 | 930 | 1,025 | +40 | +4.1% | 249,400 |
2022/12/23 | 990 | 996 | 962 | 985 | -15 | -1.5% | 79,600 |
2022/12/22 | 976 | 1,020 | 965 | 1,000 | +17 | +1.7% | 143,800 |
2022/12/21 | 977 | 1,009 | 960 | 983 | +7 | +0.7% | 153,600 |
2022/12/20 | 983 | 1,007 | 945 | 976 | -24 | -2.4% | 168,400 |
601~
650
件表示中 / 1668件
類似銘柄と比較する
現在ご覧いただいている「DELTA-P」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
DELTA-P | 63,300円 | - | - | 0.00% | - | 25.90倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
ノイルイミューン | 17,400円 | -28.6% | - | 0.00% | - | 1.75倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
ティムス | 15,800円 | - | - | 0.00% | - | 2.57倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補を中国CORXEL社に導出 |
日ケミファ | 158,300円 | +7.5% | -77.4% | 3.16% | 38.07倍 | 0.30倍 |
|
後発薬中堅、検査薬事業が第2の柱に。提携含めた新薬開発、ベトナムなど海外事業を中期強化 |
モダリス | 8,700円 | - | - | 0.00% | - | 2.12倍 |
|
遺伝子治療薬の創薬ベンチャー、DNA切断しないエピゲノム編集に強み。研究開発中心は米国 |
市場注目の銘柄
チャート関連のコラム